ADIPONECTIN IN PATIENTS WITH PRIMARY KNEE OSTEOARTHRITIS

Background: Adiponectin is a protein hormone of 244 amino acids that is abundantly produced by adipose tissues and known to have anti-inflammatory, anti-atherogenic, and cardioprotective effects. Its level correlates inversely with body mass index (BMI), glucose, insulin and triglyceride levels and is decreased in obese patients (1). Current literature data show that adiponectin levels are higher in osteoarthritis (OA) patients as compared to healthy subjects but the difference is not statistically significant in all studies. In in vitro studies both destructive and protective properties of adiponectin have been suggested. Thus, its potential role in OA is still not well-defined (2). Objectives: To assess serum adiponectin levels in patients with symptomatic primary knee OA ≥ 2 radiographic stage according to Kellgren–Lawrence scale with and without obesity. Methods: 137 patients with symptomatic primary knee OA at the age between 35 and 88 years (mean age 66 years) were included in the study (121 women and 16 men). 34 individuals including patients with obesity but without radiographic knee OA (Kellgren-Lawrence = 0) were examined as a control group. All patients underwent clinical examination and antero-posterior radiologic examination of knee joints bilaterally in a standing position. Inclusion criterion for participation in the study was presence of symptomatic and radiologically confirmed primary knee OA ≥ 2 radiographic stage according to Kellgren–Lawrence scale. Results: The mean OD values of adiponectin in OA patients with knee OA (0.104±0.018) were significantly higher as compared with the control group (0.094±0.019, p=0.0010). Interestingly, the mean values of adiponectin in obese patients with knee OA (0.101±0.018) were significantly higher as compared with those in overweight and obese controls without OA (0.086±0.010; p<0.0001). In controls without OA, cases with BMI < 25 kg/m (0.104±0.022) have shown higher adiponectin levels as compared with the patients with BMI > 25 kg/m (0.086±0.010; p=0.0029) that is known negative association between BMI and serum adiponectin levels. However, there was no significant difference in adiponectin level in patients with knee OA with (0.101±0.018) and without obesity (0.107±0.019; p=0.11). Conclusion: Decrease in serum adiponectin level in obese vs non-obese patients without accompanying diseases is well-known phenomenon. However, in knee OA such inverse association between serum adiponectin levels and BMI could not be observed and serum concentrations are significantly higher as compared with controls that suggest association of adiponectin levels with pathological process in OA. REFERENCES: [1] Nigro E, Scudiero O, Monaco ML, Palmieri A, Mazzarella G, Costagliola C, et al. New insight into adiponectin role in obesity and obesity-related diseases. Biomed Res Int. 2014;2014. [2] Ilia I, Nitusca D, Marian C. Adiponectin in Osteoarthritis: Pathophysiology, Relationship with Obesity and Presumptive Diagnostic Biomarker Potential. Diagnostics. 2022;12(2):1–10. Acknowledgements: This research was funded by the Bulgarian National Science Fund (KP-06-N33/9). Disclosure of Interests: Sevdalina Lambova Paid speaker for Astra Zeneca and BestaMed Bulgaria in the last 12 months. No conflict of interest for the current study., Tsvetelina Batsalova: None declared, Dzhemal Moten: None declared, Stela Stoyanova: None declared, Elenka Georgieva: None declared, Desislava Apostolova: None declared, Balik Dzhambazov: None declared. DOI: 10.1136/annrheumdis-2024-eular.1578 Keywords: Biomarkers, Prognostic factors Citation: , volume 83, supplement 1, year 2024, page 1420Session: Osteoarthritis and other mechanical musculoskeletal problems (Publication Only)

Biomarkers, Prognostic factors